Department of Clinical Sciences, Lund University, Malmö, Sweden.
J Am Coll Cardiol. 2010 Nov 16;56(21):1712-9. doi: 10.1016/j.jacc.2010.05.049.
the purpose of this study was to assess the predictive accuracy of conventional cardiovascular risk factors for incident heart failure and atrial fibrillation, and the added benefit of multiple biomarkers reflecting diverse pathophysiological pathways.
heart failure and atrial fibrillation are interrelated cardiac diseases associated with substantial morbidity and mortality and increasing incidence. Data on prediction and prevention of these diseases in healthy individuals are limited.
in 5,187 individuals from the community-based MDCS (Malmö Diet and Cancer Study), we studied the performance of conventional risk factors and 6 biomarkers including midregional pro-atrial natriuretic peptide (MR-proANP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-adrenomedullin, cystatin C, C-reactive protein (CRP), and copeptin.
during a mean follow-up of 14 years, 112 individuals were diagnosed with heart failure and 284 individuals with atrial fibrillation. NT-proBNP (hazard ratio [HR]: 1.63 per SD, 95% confidence interval [CI]: 1.29 to 2.06, p < 0.001), CRP (HR: 1.57 per SD, 95% CI: 1.28 to 1.94, p < 0.001), and MR-proANP (HR: 1.26 per SD, 95% CI: 1.02 to 1.56, p = 0.03) predicted incident heart failure independently of conventional risk factors and other biomarkers. MR-proANP (HR: 1.62, 95% CI: 1.42 to 1.84, p < 0.001) and CRP (HR: 1.18, 95% CI: 1.03 to 1.34, p = 0.01) independently predicted atrial fibrillation. Addition of biomarkers to conventional risk factors improved c-statistics from 0.815 to 0.842 for heart failure and from 0.732 to 0.753 for atrial fibrillation and the integrated discrimination improvement for both diseases (p < 0.001). Net reclassification improvement (NRI) with biomarkers was observed in 22% of individuals for heart failure (NRI, p < 0.001) and in 7% for atrial fibrillation (NRI, p = 0.06), mainly due to up-classification of individuals who developed disease (heart failure: 29%, atrial fibrillation: 19%). Addition of CRP to natriuretic peptides did not improve discrimination or reclassification.
conventional cardiovascular risk factors predict incident heart failure and atrial fibrillation with reasonable accuracy in middle-age individuals free from disease. Natriuretic peptides, but not other biomarkers, improve discrimination modestly for both diseases above and beyond conventional risk factors and substantially improve risk classification for heart failure.
本研究旨在评估传统心血管危险因素对心力衰竭和心房颤动事件的预测准确性,以及反映不同病理生理途径的多种生物标志物的额外益处。
心力衰竭和心房颤动是相互关联的心脏疾病,与较高的发病率和死亡率以及发病率的增加相关。关于健康个体中这些疾病的预测和预防的数据有限。
在来自基于社区的 MDCS(马尔默饮食与癌症研究)的 5187 名个体中,我们研究了传统危险因素和 6 种生物标志物(包括 midregional pro-atrial natriuretic peptide(MR-proANP)、N-terminal pro-B-type natriuretic peptide(NT-proBNP)、midregional pro-adrenomedullin、胱抑素 C、C 反应蛋白(CRP)和 copeptin)的表现。
在平均 14 年的随访期间,112 名个体被诊断为心力衰竭,284 名个体被诊断为心房颤动。NT-proBNP(风险比 [HR]:每标准差 1.63,95%置信区间 [CI]:1.29 至 2.06,p < 0.001)、CRP(HR:每标准差 1.57,95% CI:1.28 至 1.94,p < 0.001)和 MR-proANP(HR:每标准差 1.26,95% CI:1.02 至 1.56,p = 0.03)独立于传统危险因素和其他生物标志物预测心力衰竭事件。MR-proANP(HR:1.62,95% CI:1.42 至 1.84,p < 0.001)和 CRP(HR:1.18,95% CI:1.03 至 1.34,p = 0.01)独立预测心房颤动。将生物标志物添加到传统危险因素中,可使心力衰竭的 C 统计量从 0.815 提高到 0.842,心房颤动的 C 统计量从 0.732 提高到 0.753,两种疾病的综合判别改善(p < 0.001)。在心力衰竭中,生物标志物可观察到 22%的个体的净重新分类改善(NRI,p < 0.001)和 7%的个体的心房颤动(NRI,p = 0.06),主要是由于疾病患者的分类提高(心力衰竭:29%,心房颤动:19%)。CRP 加用利钠肽并不能改善判别或重新分类。
在无疾病的中年个体中,传统心血管危险因素对心力衰竭和心房颤动事件的预测具有合理的准确性。利钠肽,但不是其他生物标志物,适度提高了两种疾病的预测准确性,大大提高了心力衰竭的风险分类。